AKT1 and melanoma: In particular, activation of α5β1 integrin/PI3K/AKT signaling pathway and enhanced expression of the pro-survival myeloid cell leukemia 1 (Mcl-1) protein are associated with therapeutic escape and MAPKi resistance in melanoma [108,110].